Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
about
Eosinophilic gastroenteritis in a young girl--long term remission under Montelukast.Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independentMolecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyNovel Therapies for Eosinophilic DisordersFIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophiliaHypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapyEosinophilia in mast cell diseaseEosinophilic myeloproliferative disordersIdentification of JAK2 as a mediator of FIP1L1-PDGFRA-induced eosinophil growth and function in CELRecent advances in pathogenesis and management of hypereosinophilic syndromes.Targeting the PDGF signaling pathway in tumor treatmentRecent advances in eosinophil biology.Advances in diagnosis and treatment of eosinophiliaSerum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcomeMast cell tryptase: a review of its physiology and clinical significance.The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.Therapeutic approaches to patients with hypereosinophilic syndromes.How I treat hypereosinophilic syndromes.The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 CasesThe serum tryptase test: an emerging robust biomarker in clinical hematology.Pruritic annular patches with eosinophilia.Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.Systemic mastocytosis: bone marrow pathology, classification, and current therapies.Modern diagnosis and treatment of primary eosinophilia.Chronic myeloproliferative disorders: a tyrosine kinase tale.Eosinophilia: secondary, clonal and idiopathic.Eosinophils and disease pathogenesisCurrent concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.Gastrointestinal eosinophiliaAberrant cytokine signaling in leukemia.Oral mucosa lesions in hypereosinophilic syndrome--an update.Hypereosinophilic syndrome associated with ulcerative colitis presenting with recurrent Loeffler's endocarditis and left ventricular thrombus treated successfully with immune suppressive therapy and anticoagulation.Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.Marked and persistent eosinophilia in the absence of clinical manifestations.Secretory phospholipase A2 in the pathogenesis of acute dengue infection.Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5.Tryptase as an inflammatory marker in allergic disease and asthma.Eosinophilic diseases of the gastrointestinal tract.
P2860
Q21261874-184FF9D9-9389-4D0E-B06A-57940592D0A2Q24545984-37AA92F6-8A70-47CC-AC0E-5344703A3F60Q24685914-FF0797F1-7F4D-430D-8300-13E9BF8CB835Q26799600-4ADB2B1B-5FE7-407C-B997-AF5CECD42E74Q33404894-776272E8-4286-4D28-8A3B-0CE8DFC34DA0Q33692709-FA322256-5809-4DC2-BC44-FF65C0E2E016Q33851724-8628AA6B-7979-4339-AA9D-C9F7202A4AC9Q33881283-36CC5FB6-48E4-46EE-B499-5B3301C1B0F2Q34241738-805029C7-8116-4211-9424-1423FCD68207Q34324934-87A5F6A5-08A7-4DCC-8A4F-CFF0E1165B46Q34393461-7705077A-9A90-41C1-9891-03478BA72005Q34579906-D854D827-3B1B-453B-B7A5-FB947C3E44D2Q34895664-08523B58-461F-4C23-B539-3EA337F2D04FQ35025246-808E7D7C-6A2A-40D6-AB46-C28F55DA485AQ35807349-6B0BDC9B-6EC0-495A-8869-88C9F5A16A79Q35848279-39DC8157-F06D-47FC-A766-9348E3CA8F15Q35857340-43067968-78F6-438A-B547-8197F3762416Q36000858-3933DBB1-9197-4011-AD87-C8667A739D32Q36008991-0566DD4D-C60C-451E-B846-660D7A1F5F49Q36154674-95CB5102-1E56-4FAA-9A90-B2EE5EE22723Q36180310-E0B7B246-1C78-4ABF-9549-634B35EE8783Q36182741-9E4DC755-19B5-4EFD-8BCC-53EE0BB15BD3Q36182744-5DE01077-C57D-4695-9278-92E61E5E11B7Q36182749-0FF31D66-A286-49D1-B08E-12F607990337Q36182754-3D575186-676B-44BF-89FA-B0A63F72C718Q36337918-08AB840F-E230-4EAB-84CE-80E60F35AF0DQ36471689-C7044417-BCFE-4BA3-A5E1-1D542DE8CBC8Q36607847-16ECFE77-1BF4-4B87-976B-329C2B424721Q36811905-6DCA8769-D11A-4301-9344-A8E109FFDFB9Q36842503-50892898-CEE7-4477-9C69-4FF1C4287232Q36942155-80A5EB3A-80A2-4A9F-B744-F09C508F1BE2Q36970192-8014B6CC-D18D-467E-9809-6F10C551EFBEQ37056671-0424ADC6-1AE3-43D2-B629-00C3550DFF9FQ37223939-B35CE60E-6971-4C80-A2DE-62F8B80E4A47Q37598944-492029C5-AC72-4697-BDDA-5D8BBAB1B919Q37605322-0874C7EF-6ED7-4075-BCE6-D8570536E5C3Q37660743-2AA3EE40-6B41-4DC4-AF61-6874E38BEEACQ37755233-A54D8C31-41D0-43D2-94CB-4836CDC47C43Q37755301-71FBC3FD-2BCF-4A67-A9FD-A516A4B4CBBBQ37761380-B3609671-1C44-4391-8AD5-7F33557BA3AB
P2860
Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Elevated serum tryptase levels ...... , and imatinib responsiveness.
@en
Elevated serum tryptase levels ...... , and imatinib responsiveness.
@nl
type
label
Elevated serum tryptase levels ...... , and imatinib responsiveness.
@en
Elevated serum tryptase levels ...... , and imatinib responsiveness.
@nl
prefLabel
Elevated serum tryptase levels ...... , and imatinib responsiveness.
@en
Elevated serum tryptase levels ...... , and imatinib responsiveness.
@nl
P2093
P50
P1433
P1476
Elevated serum tryptase levels ...... , and imatinib responsiveness.
@en
P2093
Amy D Klion
D Gary Gilliland
Dean D Metcalfe
Melissa A Law
Pierre Noel
P304
P356
10.1182/BLOOD-2003-01-0006
P407
P577
2003-04-03T00:00:00Z